Saturday, June 15, 2024

Faricimab Shows Promise in Reducing Costs and Improving Efficacy for Diabetic Macular Edema Treatment

Similar articles

Diabetic macular edema (DME), a severe complication of diabetes mellitus, poses a significant threat to vision and quality of life. With the emergence of Faricimab, a bispecific antibody targeting Ang-2 and VEGF-A, new hope is on the horizon for patients suffering from this condition. This study provides a comparative evaluation of Faricimab’s clinical and economic viability against other angiogenesis inhibitors, offering crucial insights for healthcare systems.

Study Objective and Methods

The primary objective of the research was to assess the clinical and economic feasibility of Faricimab compared to other anti-angiogenic therapies such as ranibizumab and aflibercept. The study involved an extensive literature review focusing on the efficacy and safety of intravitreal injections (IVI) of these drugs. A medical care model was developed to simulate the treatment of DME patients over a 2-year period. The pharmacoeconomic analysis was executed through cost minimization and budget impact analysis (BIA) from the perspective of the Russian healthcare system.

Results and Analysis

The findings reveal that Faricimab, when administered in a personalized regimen of up to one IVI every 16 weeks, matches the safety and efficacy profile of aflibercept and ranibizumab. Importantly, Faricimab was associated with the lowest number of IVIs required. Over the 2-year modeling period, the highest costs were linked to ranibizumab treatment (approximately 914,000 rubles), while Faricimab incurred the lowest costs (614,000 rubles). Moreover, Faricimab therapy resulted in a 36% reduction in inpatient care costs compared to aflibercept and an 82% reduction compared to ranibizumab.

Economic Impact

The budget impact analysis (BIA) indicated that adopting Faricimab could alleviate the economic burden on the Russian healthcare system by 11.3 billion rubles, accounting for a 9.8% reduction over two years. These findings suggest that Faricimab is not only clinically effective but also economically advantageous.

Key Takeaways

– Faricimab requires fewer intravitreal injections compared to other therapies.

– Significant cost savings in drug therapy and inpatient care were observed with Faricimab.

– The overall economic burden on the healthcare system can be reduced substantially by using Faricimab.

In conclusion, Faricimab presents itself as a cost-effective treatment option for adults with diabetic macular edema in Russia, promising both clinical benefits and economic savings.

Original Article: Vestn Oftalmol. 2024;140(2):112-120. doi: 10.17116/oftalma2024140021112.

You can follow our news on our Telegram and LinkedIn accounts.

Subscribe to our newsletter

To be updated with all the latest news, offers and special announcements.

Latest article